Rapport Therapeutics said its investigational therapy RAP-219 delivered a 90% median reduction in seizures during the first four weeks after dosing ended, indicating durable clinical benefit. The update is positive for the company’s development program and supports the drug’s efficacy profile, though it remains early-stage and is unlikely to have broad market impact.
Rapport Therapeutics said its investigational therapy RAP-219 delivered a 90% median reduction in seizures during the first four weeks after dosing ended, indicating durable clinical benefit. The update is positive for the company’s development program and supports the drug’s efficacy profile, though it remains early-stage and is unlikely to have broad market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
